This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $637,798 to The Leland Stanford Junior University to develop a theragnostic radiopharmaceutical for the treatment of pancreatic cancer. The project aims to leverage spatial transcriptomics to identify the molecular target claudin-4 (CLDN4), which is overexpressed in pancreatic tumors, and develop peptide-based radiopharmaceuticals labeled with positron emission tomography (PET) and therapeutic beta-emitting radionuclides for patient selection, treatment, and monitoring. The research will involve in vitro assessments, xenograft/transgenic mouse model evaluations, and exploration of combination therapies with immunotherapy. The project period runs from June 1, 2024 to May 31, 2029.
Generated 2/25/25, 5:46 AM